Exkivity Wins HTA Thumbs Up In England For Rare & Aggressive NSCLC
NICE Also Confirms Spravato Rejection
The budget-neutral deal under which Takeda’s Exkivity was previously made available via the National Health Service is ending and being replaced by commercial supply at a confidential price.
